Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Eli Lilly has several exciting products in its pipeline, some of which are likely to earn approval in the next five years. Consider two of the company's leading candidates in weight loss ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...